Renaissance Technologies LLC lifted its position in Dicerna Pharmaceuticals (NASDAQ:DRNA) by 19.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 560,300 shares of the biopharmaceutical company’s stock after acquiring an additional 90,700 shares during the period. Renaissance Technologies LLC’s holdings in Dicerna Pharmaceuticals were worth $5,060,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Northern Trust Corp boosted its position in shares of Dicerna Pharmaceuticals by 6.1% in the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 2,094 shares during the period. Emerald Advisers Inc. PA acquired a new stake in shares of Dicerna Pharmaceuticals in the 4th quarter valued at about $266,000. EAM Investors LLC acquired a new stake in shares of Dicerna Pharmaceuticals in the 4th quarter valued at about $581,000. Vanguard Group Inc. boosted its position in shares of Dicerna Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock valued at $1,078,000 after purchasing an additional 14,517 shares during the period. Finally, Monashee Investment Management LLC acquired a new stake in shares of Dicerna Pharmaceuticals in the 4th quarter valued at about $1,878,000. 75.28% of the stock is owned by hedge funds and other institutional investors.
DRNA opened at $10.31 on Tuesday. The company has a market cap of $550.80, a price-to-earnings ratio of -2.82 and a beta of 2.34. Dicerna Pharmaceuticals has a 52 week low of $2.69 and a 52 week high of $15.00.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.90) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.25). The company had revenue of $1.40 million for the quarter, compared to analysts’ expectations of $1.45 million. Dicerna Pharmaceuticals had a negative net margin of 2,637.15% and a negative return on equity of 171.81%. The firm’s revenue was up 976.9% on a year-over-year basis. equities research analysts predict that Dicerna Pharmaceuticals will post -1.15 earnings per share for the current year.
A number of analysts recently issued reports on DRNA shares. ValuEngine raised Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. B. Riley started coverage on Dicerna Pharmaceuticals in a research report on Wednesday, March 28th. They issued a “neutral” rating and a $10.00 target price for the company. BidaskClub raised Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, January 25th. Zacks Investment Research cut Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, February 1st. Finally, SunTrust Banks initiated coverage on Dicerna Pharmaceuticals in a research note on Monday, February 5th. They set a “buy” rating and a $13.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $12.04.
TRADEMARK VIOLATION NOTICE: “Dicerna Pharmaceuticals (DRNA) Shares Bought by Renaissance Technologies LLC” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/17/dicerna-pharmaceuticals-drna-shares-bought-by-renaissance-technologies-llc.html.
Dicerna Pharmaceuticals Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company's preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases.
Want to see what other hedge funds are holding DRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dicerna Pharmaceuticals (NASDAQ:DRNA).
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.